Emerald Mutual Fund Advisers Trust lifted its holdings in AVROBIO, Inc. (NASDAQ:AVRO) by 31.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 932,627 shares of the company’s stock after purchasing an additional 225,745 shares during the period. Emerald Mutual Fund Advisers Trust’s holdings in AVROBIO were worth $13,001,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in AVRO. Great West Life Assurance Co. Can boosted its holdings in shares of AVROBIO by 810.7% in the third quarter. Great West Life Assurance Co. Can now owns 12,986 shares of the company’s stock worth $31,000 after buying an additional 11,560 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in shares of AVROBIO by 185.0% in the third quarter. BNP Paribas Arbitrage SA now owns 7,314 shares of the company’s stock worth $95,000 after buying an additional 4,748 shares during the period. Jane Street Group LLC acquired a new position in shares of AVROBIO in the third quarter worth about $132,000. Arizona State Retirement System acquired a new position in shares of AVROBIO in the fourth quarter worth about $142,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of AVROBIO in the third quarter worth about $213,000. 86.71% of the stock is currently owned by institutional investors.
AVRO stock opened at $15.44 on Wednesday. The stock has a market cap of $562.80 million, a P/E ratio of -4.68 and a beta of 1.41. The firm has a 50 day simple moving average of $14.60 and a 200 day simple moving average of $15.41. AVROBIO, Inc. has a 52 week low of $9.76 and a 52 week high of $29.32.
AVROBIO (NASDAQ:AVRO) last posted its earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.20). On average, analysts predict that AVROBIO, Inc. will post -3.45 EPS for the current fiscal year.
Several research analysts have commented on AVRO shares. Zacks Investment Research upgraded shares of AVROBIO from a “sell” rating to a “hold” rating in a report on Thursday, January 28th. Berenberg Bank started coverage on shares of AVROBIO in a report on Wednesday, November 11th. They issued a “buy” rating and a $27.00 target price for the company. SVB Leerink reiterated a “market perform” rating on shares of AVROBIO in a report on Thursday, November 5th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of AVROBIO in a report on Tuesday, October 6th. Finally, Morgan Stanley decreased their price target on shares of AVROBIO from $35.00 to $34.00 and set an “overweight” rating for the company in a report on Tuesday, October 13th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $30.29.
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Read More: What is the Nikkei 225 index?
Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVROBIO, Inc. (NASDAQ:AVRO).
Receive News & Ratings for AVROBIO Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AVROBIO and related companies with MarketBeat.com’s FREE daily email newsletter.